TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04741386

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination
Description: All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination
Description: All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination
Description: All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination
Description: All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
Study: NCT05964998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
Study: NCT05614661

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mom Power
Description: Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom Power
Description: Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
Study: NCT06170112

Intervention type: OTHER
Intervention: Spinal Orthosis Application
Description: Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
Study: NCT06211673

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: 3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively.

Intervention type: OTHER
Intervention: Heteroquestionnaires
Description: 7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
Study: NCT06288945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
Study: NCT04989699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-TKI/Sham
Description: OTX-TKI is one dose so subsequent visits will be sham to maintain the mask

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept/Sham
Description: Aflibercept administered every 8 weeks
Study: NCT06242054

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor Function Assessment System
Description: Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Motor Function Assessment System
Description: Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
Study: NCT05212896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC006
Description: BC006 monoclonal antibody injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC006
Description: BC006 monoclonal antibody injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC006
Description: BC006 monoclonal antibody injection
Study: NCT06493487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated neuromuscular inhibition technique
Description: integrated neuromuscular inhibition technique for gastrocniemus muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assissted soft tissue mobilization
Description: instrument assissted soft tissue mobilization for calf muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: convential treatment
Description: convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
Study: NCT06393790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMG (Fibromyalgia group)
Description: This intervention will report results of a strength training programme in people with fibromyalgia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HG (Healthy group)
Description: This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
Study: NCT04828083

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Study: NCT04596384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TapCloud
Description: Use TapCloud app
Study: NCT05979246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lance CLEAR dental implant
Description: The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
Study: NCT04828083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline IV
Description: Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Study: NCT06493331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking Circle
Description: step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received.
Study: NCT05829590

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
Study: NCT05976412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional lymph node radiotherapy
Description: Regional lymph node radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest/whole breast irradiation
Description: chest/whole breast irradiation

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: chest/whole breast irradiation
Description: chest/whole breast irradiation
Study: NCT05072600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg Q3W
Study: NCT06447714

Intervention type: BEHAVIORAL
Intervention: smoke
Description: cotinine detection
Study: NCT05455710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VigiApp
Description: mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VigiApp
Description: mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
Study: NCT05549778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polaprezinc group
Description: Abiraterone plus Polaprezinc for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Abiraterone, radio- or chemotherapy
Study: NCT05117697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral subcutaneous sphincterotomy
Description: Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral subcutaneous sphincterotomy
Description: Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.
Study: NCT06032338

Intervention type: OTHER
Group type: OTHER
Intervention: CRC screening invitation not including the screening test.
Description: The invitation to CRC-PBOSP will only contain informations on how to get the screening test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailing of FIT with invitation
Description: The invitation to CRC-PBOSP will contain the CRC screening test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailing of FIT with invitation
Description: The invitation to CRC-PBOSP will contain the CRC screening test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information letter before invitation
Description: An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
Study: NCT06113484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIET + EXERCISE
Description: At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: WITHOUT DIET + EXERCISE
Description: An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases.
Study: NCT04885036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFST intervention
Description: EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
Study: NCT06330883

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognosis
Description: survival/mortalite

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognosis
Description: survival/mortalite
Study: NCT06491082

Intervention type: DRUG
Intervention: Cisplatin, Carboplatin, Paclitaxel, Docetaxel
Description: Solid cancer Patients receiving any one drug or in combination
Study: NCT04631926

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hip Muscle Exercise
Description: Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
Study: NCT04936841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Description: immunotherapy drug, monoclonal antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation
Description: radiation to relieve symptoms
Study: NCT05001451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GDX012 Suspension for IV Infusion
Description: Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion
Study: NCT04296097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)

Intervention type: DEVICE
Group type: OTHER
Intervention: DBS
Description: Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
Study: NCT05216757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iguratimod
Description: iguratimod, 25mg bid po.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet bid po.
Study: NCT06102603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the biobased polyester cast
Description: long arm casting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the synthetic fiberglass cast
Description: long arm casting
Study: NCT05520645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: use etomidate for anesthesia induction in hysteroscopic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: use etomidate for anesthesia induction in hysteroscopic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: use etomidate for anesthesia induction in hysteroscopic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: use propofol for anesthesia induction in hysteroscopic surgery
Study: NCT05955404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Description: This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
Study: NCT05487339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: fascial plane injection guided by fluoroscopy device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: fascial plane injection guided by fluoroscopy device
Study: NCT05033665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase water consumption
Description: The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain adequate water consumption
Description: The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
Study: NCT04311216

Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements

Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
Study: NCT05096351

Intervention type: OTHER
Intervention: Blood test
Description: Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
Study: NCT05128825

Intervention type: DRUG
Group type: OTHER
Intervention: ZN-c3
Description: ZN-c3 is an investigational drug.
Study: NCT04813926

Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Follow clinical practice.
Study: NCT05593666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXE408
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXE408
Description: Film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome®
Description: Sterile lyophilised powder in a 15 mL sterile clear glass vial
Study: NCT05227872

Intervention type: DEVICE
Intervention: ultrasound
Description: POCUS

Intervention type: DEVICE
Intervention: ultrasound
Description: POCUS
Study: NCT05197413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arrae bloat supplement
Description: The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
Study: NCT05975684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: 0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 4 weeks
Study: NCT05510596

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging with contrast injection
Description: Magnetic Resonance Imaging with contrast injection

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: Blood withdrawal : serum, plasma, cytokine assay

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological tests
Description: Neuropsychological tests
Study: NCT04823247

Intervention type: DRUG
Intervention: Tildrakizumab
Description: As provided in real world clinical practice.